Tarsus Pharmaceuticals, Inc.
TARS · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $451M | $183M | +147% |
| Operating income | −$71.0M | −$121M | +41.1% |
| Net income | −$66.4M | −$116M | +42.5% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 3, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $195M | $119M | +63.9% |
| Operating income | −$662M | −$14.5M | −4,466% |
| Net income | −$668M | −$12.6M | −5,204% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Tarsus's revenue in FY2025?
- $451M in FY2025 (Fiscal year ended Dec 31, 2025), +147% vs $183M a year earlier, per its 10-K filed Feb 2026.
- Was Tarsus profitable in FY2025?
- No: net income was −$66.4M and operating income −$71.0M in FY2025.
- What was Tarsus's revenue in Q3 2026?
- $195M (+63.9% vs a year earlier), per its Form 10-Q filed Nov 3, 2026.